Researchers analyzed data from 488,079 participants in the UK Biobank to investigate relationships between chronic systemic inflammation and heart health. Chronic inflammation was measured using glycoprotein acetyls (GlycA) as the biomarker. The analysis examined associations between GlycA and cardiac structure and function, the occurrence of major adverse cardiovascular events, and how environmental exposures and genetics might interact with inflammatory status.
The study found that higher GlycA levels were associated with measurable changes in heart structure and performance. Specifically, people with elevated GlycA tended to have a smaller left ventricular volume, greater wall thickness, and reduced diastolic function. These structural and functional differences are consistent with pathways that can compromise cardiac performance over time and are frequently observed in conditions that increase cardiovascular morbidity.
Higher GlycA was also associated with a greater risk of major adverse cardiovascular events, including heart attack, stroke, and heart failure. In commentary included with the report, Cheng-Han Chen, MD, noted that study participants with the highest GlycA levels had a 43% higher risk of experiencing a major cardiovascular event compared with those with the lowest GlycA levels. The authors and external experts cautioned that this association does not establish causation; further research is necessary to determine whether GlycA is a prognostic biomarker or a target for intervention.
The investigators identified several modifiable and social/environmental factors associated with increased GlycA. These included:
The article highlights that excess fat around the abdomen is metabolically active and linked with inflammation and poorer glycemic control. Smoking was noted to raise inflammation and damage blood vessels. Psychological distress was described as contributing indirectly to risk by affecting sleep, activity levels, diet choices, and smoking behaviors. The study authors framed these links as evidence that everyday exposures and conditions are closely tied to systemic inflammatory profiles.
Conversely, the analysis found that higher levels of physical activity and adherence to a healthier diet correlated with lower GlycA. Higher socioeconomic status was also associated with lower GlycA levels. The expert commentary emphasized that regular physical activity and a nutrient-dense, minimally processed diet have previously been associated with reduced chronic inflammation and improved cardiovascular health, which aligns with the study findings. Authors and commentators stressed that while lowering GlycA specifically has not been proven to prevent cardiovascular events, established lifestyle measures remain central to reducing overall cardiovascular risk.
The researchers examined genetic susceptibility alongside environmental exposures and reported that genetics “significantly modifies” the relationship between inflammation and environmental factors. In other words, inherited characteristics may influence how strongly an individual’s inflammatory profile responds to factors such as diet, physical activity, smoking, body composition, and stress. Experts in the article framed this as evidence that both inherited and modifiable factors shape inflammatory status and cardiovascular risk.
Two clinicians who were not involved in the study placed the findings in clinical context. Cheng-Han Chen, MD, an interventional cardiologist, described the magnitude of the association (43% greater risk in the highest GlycA group) as meaningful but reiterated that the evidence does not prove causality; he called for further research to establish whether GlycA can serve as a reliable prognostic biomarker.
A preventive cardiology dietitian, Michelle Routhenstein, MS, RD, CDCES, CDN, characterized GlycA as one piece of cardiovascular risk assessment that should be interpreted alongside established markers such as ApoB or LDL cholesterol, blood pressure, blood sugar, visceral adiposity, smoking status, and overall cardiovascular history. She emphasized that GlycA is a risk marker rather than a diagnostic target on its own.
Both experts highlighted the practical takeaway that lifestyle interventions—improving diet quality, increasing physical activity, addressing abdominal adiposity, smoking cessation, and managing stress and metabolic risk factors—remain important for reducing inflammation and cardiovascular risk, irrespective of genetic background.
Note on population prevalence and study limitations
The article notes prior estimates that roughly 34% of adults in the United States have systemic inflammation, a context that underscores the potential public health relevance of inflammation-related risk. The original analysis used UK Biobank data and reported associations but did not establish causal pathways; detailed methodological limitations, follow-up duration, and other study design specifics beyond the participant number and measured associations were not reported in the source article.
Clinical implication
This large observational analysis links elevated GlycA to adverse cardiac structural and functional findings and to a higher observed risk of MACE, while identifying both modifiable risk factors and genetic modifiers of that risk. Clinicians should consider GlycA as an emerging inflammatory risk marker that complements traditional risk assessment, while prioritizing evidence-based lifestyle and metabolic management strategies that lower overall cardiovascular risk.